Clinical-stage biotechs usually reach the end of a Phase 3 trial with a shrinking cash balance and a discounted raising in prospect. Dimerix (ASX:DXB) has taken another route, licensing its lead kidney drug across five regions and, in early September, adding a A$34 million Loan Facility that avoids new shares. Shares traded at A$0.24 on 14 September 2026 for a Market Capitalisation near A$150.09 million, and the company says it is funded to the end of its pivotal trial.

Latest Development

After a Trading halt on 2 September, Dimerix announced on 4 September 2026 a A$34 million non-dilutive funding facility from Australian and United States lenders. Half, or A$17 million, was to be drawn by 18 September 2026, with the balance available at the company's discretion until 31 March 2027 and an option to expand commitments by that date.

Interest runs at 10 per cent per annum, compounding annually, with repayment due on 17 January 2028. Unrelated lenders hold security under a general security deed, while SKIPTAN Pty Ltd entities, which committed A$12 million, remain unsecured pending an ASX waiver. Lenders take 30 per cent of DMX-200 milestone payments, capped at twice the amount drawn.

Company Overview

Dimerix has been ASX-listed since February 1993 and develops therapies for inflammatory and kidney disease. Lead candidate DMX-200 is a CCR2 inhibitor used with background angiotensin II receptor blocker therapy for focal segmental glomerulosclerosis, a rare disease that scars the kidney's filtering units. It holds Orphan Drug designations in key markets.

A second candidate, DMX-652, was acquired more recently: an oral, once-daily USP30 inhibitor described as first-in-class in targeting mitophagy, aimed at preventing acute kidney injury in high-risk cardiac surgery patients. A Phase 1 study in 85 healthy volunteers recorded no serious adverse events.

Recent Developments

An investor presentation on 7 September 2026 confirmed the ACTION3 Phase 3 trial is fully recruited, with 333 adult patients against a target of at least 286. It passed a blinded futility assessment based on 72 patients at 35 weeks and remains more than 90 per cent powered for its proteinuria endpoint, measured as urinary protein-to-creatinine ratio at 104 weeks.

Of 81 patients eligible for the open label extension, 75 have enrolled. Paediatric recruitment continues and is not expected to affect final analysis timing.

Financial and Operational Position

Cash stood at A$16.2 million at June 2026, alongside A$48.1 million of further identified resources: the A$34 million facility plus a A$14.1 million upfront from Everest, its partner for China, South Korea and South-East Asia. Dimerix states it is funded through completion of ACTION3 and the DMX-652 Phase 2 program.

Five regional licences for DMX-200 have generated more than A$80 million in upfront payments and carry up to A$237 million in development milestones, plus sales milestones of about A$1.56 billion and royalties from low teens to above 30 per cent by territory. Roughly 600.4 million shares were on issue.

What Investors May Watch Next

The ACTION3 readout, due about 104 weeks from completion of randomisation, is the central event. Nearer term, investors may be watching paediatric recruitment, progress on a regulatory dossier, and the DMX-652 Phase 2 schedule, which targets first patient dosing in the first half of 2027 and a readout in the first half of 2028.

Risks

Phase 3 trials fail, and a futility pass is not evidence of efficacy. The facility carries a 10 per cent compounding coupon, security over Assets and a claim on milestone income, so it shifts rather than removes financing risk. Milestone and Royalty income depends on partners progressing the asset.

Conclusion

Dimerix reaches September 2026 with a fully recruited pivotal trial, partners across most major markets and a funding structure designed to avoid dilution before data arrives. Whether it stays in focus may depend less on cash than on the ACTION3 result, which in either direction would settle the value of an asset already licensed five times over.